The innovative partnership seeks to revolutionize decentralized genomic testing, offering swift turnaround times to identify individuals who may benefit from Bayer's array of precision cancer treatments.

Harnessing Thermo Fisher's Oncomine Dx Express Test* on the Ion Torrent Genexus Dx System*, a fully integrated NGS platform capable of delivering results within 24 hours, the collaboration aims to streamline the identification of patients suitable for Bayer's precision cancer therapies.

Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceuticals Division and Head of the Oncology Strategic Business Unit, expressed Bayer's commitment to advancing precision medicine, stating, "We are dedicated to expanding treatment options for patients with unmet medical needs and reducing exposure to ineffective treatments. This collaboration perfectly aligns with Bayer's precision medicine strategy and our mission to advance genomic testing and personalized treatment in Oncology."

Garret Hampton, President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific, echoed Roth's sentiments, emphasizing the potential impact of their combined efforts on patient outcomes. "Our goal is to provide rapid next-generation sequencing solutions that support access to targeted therapies, ultimately improving patient outcomes," Hampton said. "With our Genexus Dx System's unparalleled turnaround time and Bayer's expanding precision oncology portfolio, we are poised to ensure eligible patients are swiftly matched with the most appropriate treatment."

Financial details of the collaboration were not disclosed.

*The Genexus Dx instrument and the Oncomine Dx Express Test are currently CE-IVD and are only available in countries that accept the CE mark.